Outsourcing Perspectives from Mark Rogers of SGS Life Science Services - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Outsourcing Perspectives from Mark Rogers of SGS Life Science Services
Mark Rogers, senior vice president at SGS Life Science Services, provided commentary on the evolving role of contract services in analytical services.


Technical/Scientific Trends

Analytical services

PharmTech: What emerging technologies or practices do drug sponsors expect your organization to provide?

Mark Rogers: It is very important for a service provider to maintain existing technologies but also to keep up to date with developing equipment and methodologies. Mass spectrometry, for example, has evolved from a research tool to a technique that is often now expected in QC environments. Quality is perhaps the single most important aspect of all practices demanded by drug sponsors.

PharmTech: What scientific or technical advances have positively or negatively impacted drug development processes in this market segment?

Mark Rogers: Generally, the ability to automate analytical processes has made significant impact on precision and speed.  A move towards UPLC technology allows for increases in the rate of analytical testing in the field of liquid chromatography although, due to the increased efficiency, such development can lead to an often unwanted re-evaluation of the product composition.

PharmTech: Are you seeing shifts in demand for particular types of services? Please describe.

Mark Rogers: In the specific area of biopharmaceutical testing, there has been an unmistakable expansion into services that allow higher order structures to be defined. Such techniques are now applied in characterization of primary products as well as for comparability studies such as in the testing of in biosimilars.

PharmTech: What pressing technical challenges have you seen in this market segment? What actions has your company taken to resolve the challenge? What actions does your company suggest?

Mark Rogers: One of the many technical challenges lies in definition of biotherapeutic impurities. Such studies often demand a multidisciplinary approach in terms of technology and expertise. SGS is able to respond to such requirements by maintaining a broad base of scientific experts and diversity within laboratory instrumentation which is continually updated. 

PharmTech: What advances do you see in science or technology in this market segment in the next five years?

Mark Rogers: Traditionally, there has always been a demand for increased rate of testing and this will continue with advances in automation and application of technologies such as UPLC. In the biopharmaceutical testing field, advances in sensitivity and miniaturization will become critical, particularly with the evolution of individual patient therapies. Techniques such as FTIR may also advance to allow non-destructive, continuous screening which may find application in, for example, stability programs.

Industry Trends

PharmTech: What changes are you observing in the organization and operations of drug sponsors in this market segment?

Mark Rogers: There has been a trend, particularly in the small/mid-size drug sponsors or those new to the biopharmaceutical market, towards a more consultation-type relationship with the service provider.  Rather than simply asking for a pre-determined list of tests, service providers are now becoming much more involved in experimental design and assistance with regulatory issues.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here